Advanced Search

Show simple item record

dc.contributor.authorEl, Cheikh, J.
dc.contributor.authorNgoya, M.
dc.contributor.authorGalimard, J.-E.
dc.contributor.authorReményi, P.
dc.contributor.authorKulagin, A.
dc.contributor.authorAljurf, M.
dc.contributor.authorMousavi, A.
dc.date.accessioned2025-01-12T18:55:07Z
dc.date.available2025-01-12T18:55:07Z
dc.date.issued2024
dc.identifier.issn0003-469X
dc.identifier.urihttps://doi.org/10.1038/s41409-024-02300-8
dc.identifier.urihttp://hdl.handle.net/11446/5059
dc.description.abstractT-cell acute lymphoblastic leukemia (T-ALL) predominantly affects individuals in late childhood and young adulthood. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative modality particularly in the setting of poor risk genetics and/or persistent minimal residual disease. Limited studies have directly explored the impact of patient- and transplant-related factors on post-transplant outcomes in T-ALL. Using a large dataset from the European Society for Blood and Marrow Transplantation registry, we identified 1907 adult T-ALL patients (70% male) who underwent their first allo-HSCT in first complete remission (CR1) from matched sibling donors (MSD; 45%), unrelated donors (UD; 43%) or haploidentical donors (12%) between 2010 and 2021. The median age at transplant was 33.4 years (18.1–75). The median follow up was 2.9 years. Most patients underwent total body irradiation (TBI)-based myeloablative conditioning (69%). The 2-year overall survival (OS) was 69.4%, and leukemia -free survival (LFS) was 62.1%. In multivariate analysis, advanced age at transplant negatively affected LFS (for each 10-year increment, HR = 1.11, p = 0.004), GVHD-free, relapse-free survival (GRFS) (HR = 1.06, p = 0.04), OS (HR = 1.12, p = 0.002), and non-relapse mortality (NRM) (HR = 1.23, p < 0.001). More recent years of allo-HSCT were associated with improved GFRS (For each 3-year increment, HR = 0.89, p < 0.001), OS (HR = 0.9, p = 0.02), and decreased NRM (HR = 0.82, p = 0.008). TBI improved LFS. (HR = 0.79, p = 0.02), GRFS (HR = 0.83, p = 0.04), and relapse incidence (RI) (HR = 0.65, p < 0.001). Female-to-male transplant negatively affected GRFS (HR = 1.21, p = 0.02) and OS (HR = 1.23, p = 0.048). In vivo T-cell depletion significantly improved GFRS (HR = 0.74, p < 0.001). This large study identified prognostic factors, such as age at transplant conditioning regimen, in influencing post-transplant in adult T-ALL patients undergoing allo-HSCT. Importantly, a significant improvement over time was noted. These findings hold great promise for new adapted treatment strategies and can serve as a benchmark for future studies in that setting. © The Author(s), under exclusive licence to Springer Nature Limited 2024.en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.identifier.doi10.1038/s41409-024-02300-8
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectFemaleen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPrecursor T-Cell Lymphoblastic Leukemia-Lymphomaen_US
dc.subjectPrognosisen_US
dc.subjectRegistriesen_US
dc.subjectSurvival Rateen_US
dc.subjectTransplantation Conditioningen_US
dc.subjectYoung Adulten_US
dc.subjectalemtuzumaben_US
dc.subjectcyclophosphamideen_US
dc.subjectcyclosporineen_US
dc.subjectglobulinen_US
dc.subjectmethotrexateen_US
dc.subjectmycophenolate mofetilen_US
dc.subjectacute leukemiaen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectallogeneic hematopoietic stem cell transplantationen_US
dc.subjectArticleen_US
dc.subjectbone marrowen_US
dc.subjectchronic graft versus host diseaseen_US
dc.subjectCytomegalovirusen_US
dc.subjectdisease free survivalen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectgraft versus host reactionen_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmortalityen_US
dc.subjectoutcome assessmenten_US
dc.subjectoverall survivalen_US
dc.subjectprognosisen_US
dc.subjectrecurrence free survivalen_US
dc.subjectT cell acute lymphoblastic leukemiaen_US
dc.subjectadolescenten_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjectmiddle ageden_US
dc.subjectproceduresen_US
dc.subjectprognosisen_US
dc.subjectregisteren_US
dc.subjectsurvival rateen_US
dc.subjectT cell acute lymphoblastic leukemiaen_US
dc.subjecttherapyen_US
dc.subjecttransplantation conditioningen_US
dc.subjectyoung adulten_US
dc.titlePrognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working partyen_US
dc.typearticleen_US
dc.departmentDBÜen_US
dc.identifier.issue9en_US
dc.identifier.volume59en_US
dc.identifier.startpage1239en_US
dc.identifier.endpage1246en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempEl Cheikh J., Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Ngoya M., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Galimard J.-E., EBMT Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, France; Reményi P., Dél-pesti Centrumkórház –Országos Hematológiai és Infektológiai Intézet, Dept. Haematology and Stem Cell Transplant, Albert—Budapest, Budapest, Hungary; Kulagin A., RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation; Aljurf M., King Faisal Specialist Hospital & amp; Research Centre, Oncology (Section of Adult Haematolgy/BMT)—Riyadh, Riyadh, Saudi Arabia; Mousavi A., Shariati Hospital, Hematology-Oncology and BMT Research—Teheran, Tehran, Iran; Wu D., First Affiliated Hospital of Soochow University, Department of Hematology—Suzhou, Suzhou, China; Ozcelik T., Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Hematopoietic SCT, Unit—Istanbul, İstanbul, Turkey; Salmenniemi U., HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit—Helsinki, Helsinki, Finland; Castilla-Llorente C., Gustave Roussy Cancer Campus, BMT Service, Deen_US
dc.identifier.pmid38834689en_US
dc.identifier.scopus2-s2.0-85195171247en_US
dc.identifier.wosWOS:001365375000013en_US
dc.authorscopusid57190088309
dc.authorscopusid57226109363
dc.authorscopusid57189886743
dc.authorscopusid6603458868
dc.authorscopusid57788890000
dc.authorscopusid55863021500
dc.authorscopusid57222718733


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record